Parkinson's disease

There are 4,365 papers on Parkinson's disease in aging research: 492 trials and 1,428 observational studies in people, 481 in animals, 42 in cells, 1,706 reviews. The newest story, Nov 16, 2026: “Agent Orange exposure linked to Parkinson disease in US veterans”.

Disease

4,365 papers study it1,752 more mention it1,382 findings

MeSH

147 new papers in 30 daysSee all 6,117 papers on Parkinson's disease

“DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92])”
Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trialsDiabetes, obesity & metabolism2024doi:10.1111/dom.16147
  • Human trial492
  • Humans1,428
  • Animals321
  • Model organisms160
  • Cells42
  • In silico122

Interventions

40

GLP-1 receptor agonists

no changein humans5HR 0.9–1.04

5 studies
  1. GLP-1 receptor agonists were not clearly linked with Parkinson's disease in humans (HR 0.90 (0.67-1.22)).

    “PD occurred in 231 GLP-1 RA users (1.0%) and 338 non-GLP-1 users (1.4%) (0.90 (0.67-1.22)).”

    Humans1:1 matched cohort vs non-GLP-1 glucose-lowering medications; adults with type 2 diabetes and obesity

    GLP-1 diabetes drugs linked to lower risk of dementia

    European journal of internal medicine

  2. GLP-1 receptor agonists were not clearly linked with Parkinson's disease in humans (Patients with type 2 diabetes initiating therapy; compared with new metformin users) (aHR 0.91, 95% CI 0.79–1.05).

    “The overall PD risk was comparable between GLP-1RA and metformin groups (aHR, 0.91; 95% CI, 0.79-1.05).”

    HumansPatients with type 2 diabetes initiating therapy; compared with new metformin users

    GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes

    Diabetes, obesity & metabolism

  3. GLP-1 receptor agonists were not clearly linked with Parkinson's disease in humans (compared with dipeptidyl peptidase-4 inhibitors) (HR 1.04 [95% CI 0.93 to 1.17]).

    “hazard ratios for dementia, Alzheimer's disease, vascular dementia, and Parkinson's disease onset were 0.76 [0.72 to 0.81], 0.77 [0.68 to 0.87], 0.75 [0.67 to 0.85], and 1.04 [0.93 to 1.17]”

    Humanscompared with dipeptidyl peptidase-4 inhibitors4.0-year mean follow-upn = 214,442

    Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study

    Cardiovascular diabetology

  4. GLP-1 receptor agonists were not clearly linked with Parkinson's disease in adults with type 2 diabetes and obesity, propensity-score matched.

    “with no significant differences in the risk of Parkinson disease or intracerebral hemorrhage”

    Humansin adults with type 2 diabetes and obesity, propensity-score matched7-year follow-upn = 60,860

    Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

    JAMA network open

  5. GLP-1 receptor agonists were not clearly linked with Parkinson's disease in obese patients, all GLP-1 receptor agonist users (RR 0.784, 95% CI 0.580-1.058).

    “The risk reduction for Parkinson's disease was not statistically significant overall (RR = 0.784, 95 %CI = 0.580-1.058)”

    Humansin obese patients, all GLP-1 receptor agonist users

    Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study

    International immunopharmacology

More on GLP-1 receptor agonists

Physical activity

no changein humans3downin humans1HR 0.77

4 studies
  1. Physical activity was not clearly linked with Parkinson's disease in humans (prodromal Parkinson's disease) (p-values > 0.05).

    “physical activity (as assessed by the total, household-related, leisure-related, and work-related scores) had no significant associations with disease severity and cognitive function (p-values > 0.05)”

    Humansprodromal Parkinson's diseasefour-yearn = 108

    The relationship between physical activity levels and measures of cognition and disease severity in prodromal Parkinson's disease: A longitudinal study

    BMC neurology

  2. Physical activity was not clearly linked with Parkinson's disease in humans (excluding follow-up periods closer to the time of accelerometer wear).

    “However, this association was no longer statistically significant when excluding follow-up periods closer to the time of accelerometer wear”

    Humansexcluding follow-up periods closer to the time of accelerometer wear

    Daily steps are a predictor of, but perhaps not a risk factor for Parkinson's disease: findings from the UK Biobank

    NPJ Parkinson's disease

  3. Physical activity was not clearly linked with Parkinson's disease in humans (active WW vs active regular) (HR = 0.77, 95% CI = 0.56-1.05, P = 0.099).

    “no statistically significant difference was observed between the active WW and the active regular groups (HR = 0.77; 95% CI = 0.56-1.05; P = 0.099).”

    Humansactive WW vs active regularn = 89,400

    Association of physical activity pattern and risk of Parkinson's disease

    NPJ digital medicine

  4. Physical activity protects against Parkinson's disease in humans.

    “Well-supported factors include physical activity, adherence to a Mediterranean diet, and caffeine or tea consumption as protective factors”

    Review

    Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions

    Neurological research and practice

More on Physical activity

Proton-pump inhibitors

no changein humans1HR 0.95

1 study
  1. Proton-pump inhibitors were not clearly linked with Parkinson's disease in humans (Adults with upper gastrointestinal disorders; overall use; IPTW analysis) (IPTW HR 0.95 (95% CI 0.89–1.02); PSM HR 0.93 (95% CI 0.84–1.03)).

    “Overall PPI use was not significantly associated with PD risk”

    HumansAdults with upper gastrointestinal disorders; overall use; IPTW analysisseven years preceding the index date

    Cumulative proton pump inhibitor exposure and risk of Parkinson’s disease: a nationwide cohort study

    Scientific reports

More on Proton-pump inhibitors

Ultrafine particles

no changein humans1

1 study
  1. Ultrafine particles were not clearly linked with Parkinson's disease in humans.

    “We did not observe effects of UFP on mortality from Parkinson's disease or amyotrophic lateral sclerosis.”

    Humans2001-2019

    Ultrafine particle exposure linked to dementia mortality

    Epidemiology (Cambridge, Mass.)

More on Ultrafine particles

Tobacco

downin humans1

1 study
  1. Tobacco is linked with lower Parkinson's disease in humans.

    “Tobacco exposure exerted a negative modulatory effect on PD burden”

    Humans

    A multi-omics insight into the sex-specific burden of tobacco-associated neurodegeneration: trends, projections, and mechanistic clues from the TH gene

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

More on Tobacco

Intermittent energy restriction

downin mice1

1 study
  1. Intermittent energy restriction protects against Parkinson's disease in PD mice.

    “IER exerts neuroprotective effects to delay PD progression by regulating the gut microbiota-metabolite axis”

    Animalsin PD mice

    Metabolomic-microbiomic integrated analysis reveals the role of intermittent energy restriction in Parkinson's disease

    Neurodegenerative disease management

More on Intermittent energy restriction

Estradiol

no changein humans1

1 study
  1. Estradiol was not clearly linked with Parkinson's disease in humans (tested by mediation analysis with 2,000 bootstrap resamples) (indirect effect = -0.0054, P = 0.300; 5.7% mediated).

    “Estradiol did not mediate the MetS-PD association (indirect effect = − 0.0054, P = 0.300; 5.7% mediated).”

    Humanstested by mediation analysis with 2,000 bootstrap resamplesfemales

    Metabolic Syndrome and Parkinson‘s Disease in Chinese Women: Menopausal Status as an Effect Modifier

    Research SquarePreprint

More on Estradiol

Walking exercise + blood flow restriction

downin humans1

1 study
  1. Walking exercise + blood flow restriction decreases Parkinson's disease in humans (Parkinson's disease).

    “and total UPDRS scores, with additional reductions in UPDRS Parts II-IV”

    Human trialParkinson's disease8 weeksn = 8

    Walking with blood flow restriction in Parkinson's disease: vascular, neurotrophic and functional outcomes: a randomized controlled trial (WALK-BFR-PD Trial)

    European journal of applied physiology

More on Walking exercise + blood flow restriction

Selenomethionine

no changein humans1

1 study
  1. Selenomethionine showed no clear effect on Parkinson's disease in humans (post-intervention follow-up).

    “Associations were near null for leukemia, non-Hodgkin lymphoma and Parkinson's disease”

    Human trialpost-intervention follow-upL-selenomethionine200 μg7-12 yearsmalesn = 34,887

    The selenium and vitamin E cancer prevention trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration

    American journal of epidemiology

More on Selenomethionine

PCSK9-targeted therapies

no changein humans1OR 0.82

1 study
  1. PCSK9-targeted therapies showed no clear effect on Parkinson's disease in humans (OR 0.82 (95% CI 0.11-6.37)).

    “no significant association was observed for the risk of dementia and Parkinson's disease”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on PCSK9-targeted therapies

Exercise

downin humans1

1 study
  1. Exercise decreases Parkinson's disease in humans (chronic Parkinson's disease) (stage 3 (IQR: 3-4) to 2 (IQR: 2-3), p < 0.001).

    “Disease severity reduced significantly, with Hoehn and Yahr stages decreasing from 3 (IQR: 3-4) to 2 (IQR: 2-3) (p < 0.001).”

    Human trialchronic Parkinson's diseasefive days per week, 45 minutes per sessionsix weeksn = 20

    Effect of Structured Exercise for the Rehabilitation of Patients With Chronic Parkinson's Disease

    Cureus

More on Exercise

All 40

Effects

90

Gait speed

downin humans3

3 studies
  1. Parkinson's disease is linked with worse gait speed in humans (compared to controls).

    “Compared to controls, participants with PD showed poorer gait performance, with lower preferred walking speed and shorter step length in both gait conditions.”

    Humanscompared to controls

    Maximal Handgrip Strength as a Measure of General Functional Capacity Rather than Parkinson's Disease-Specific Impairment

    Brain sciences

  2. Parkinson's disease is linked with lower gait speed in humans (preferred and fast walking speeds).

    “PwPD group had significantly greater falls risk and walked slower than healthy elderly.”

    Humanspreferred and fast walking speedsn = 25

    Relationships between falls risk, gait speed, and head-trunk control in people with Parkinson's disease and elderly

    Clinical biomechanics (Bristol, Avon)

  3. Parkinson's disease is linked with worse gait speed in humans (participating in a community-based exercise program).

    “Adults with PD showed significantly lower physical performance than community-dwelling older adults, with gait speed exhibiting the largest between-group difference.”

    Humansparticipating in a community-based exercise program

    Physical performance and DEXA-derived body composition in adults with Parkinson's disease participating in a community-based exercise program and community-dwelling older adults: a cross-sectional study

    Scientific reports

Cognitive function

downin humans3

3 studies
  1. Parkinson's disease decreases cognitive function in humans.

    “Performance followed expected significant trends across language-speaking cohorts: young adults (YA)>older adults (OA)>people with Parkinson's Disease (PwP), confirming discriminative abilities.”

    Human trialn = 250

    Breaking geographic and language barriers in neuropsychology: online administration of MoCA in diverse populations

    NPJ digital medicine

  2. Parkinson's disease impairs cognitive function in humans (all conditions collapsed).

    “All conditions collapsed, the efficiency of the cognitive task was significantly lower in PwPD than HE, whilst accuracy was affected to a lower extent.”

    Human trialall conditions collapsedn = 40

    The Effect of Upright Stance and Vision on a Cognitive Task in Elderly Subjects and Patients with Parkinson's Disease

    Brain sciences

  3. Parkinson's disease is linked with worse cognitive function in humans (compared to age-matched healthy controls).

    “Compared to age-matched healthy controls, people with PD (pwPD) showed impaired cognitive performance, alongside reduced central functional connectivity.”

    Humanscompared to age-matched healthy controls

    Functional connectivity in neurologically healthy aging and Parkinson's Disease: Investigating the role of age and medication

    The European journal of neuroscience

Physical function

downin humans2

2 studies
  1. Parkinson's disease is linked with worse physical function in humans (Parkinson's disease) (SPPB: p = 0.004; TUG: p = 0.002; walking speed: p = 0.001).

    “poorer physical function (SPPB: p = 0.004; TUG: p = 0.002; walking speed: p = 0.001)”

    HumansParkinson's diseasen = 20

    Lower-limb rate of torque development, but not peak torque, is associated with balance performance in older adults with and without Parkinson’s disease: a cross-sectional study

    Sport Sciences for Health

  2. Parkinson's disease is linked with worse physical function in humans (manual tracking task).

    “Younger controls (YC) performed fewer tracking errors than older participants (both PwP and OC), and OC performed better than PwP.”

    Humansmanual tracking task

    Submovements in manual tracking: people with Parkinson's disease produce more submovements than age-matched controls

    Journal of neuroengineering and rehabilitation

Zonulin

no changein humans2

2 studies
  1. Parkinson's disease was not clearly linked with zonulin in humans (Parkinson's disease).

    “Compared to controls, zonulin levels were generally increased in PD patients; however, the difference was statistically insignificant (p = 0.289).”

    HumansParkinson's diseaseserumn = 119

    Of the manuscript: relationship between serum Zonulin level and sarcopenia in Parkinson's disease

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

  2. Parkinson's disease showed no clear effect on zonulin in humans (Parkinson's disease compared to non-PD) (MD = 26.88 ng/mL; 95 % CI = -29.26-83.01, p = 0.35).

    “There was, however, no significant difference in faecal zonulin between PD and non-PD individuals”

    ReviewParkinson's disease compared to non-PD

    Faecal intestinal permeability and intestinal inflammatory markers in older adults with age-related disorders: A systematic review and meta-analysis

    Ageing research reviews

More on Zonulin

Brain age

upin humans1upin silico1

2 studies
  1. Parkinson's disease is linked with higher brain age in humans (Parkinson disease).

    “We found increased global and regional brain age in PD patients.”

    HumansParkinson disease

    Multiscale brain age prediction reveals region-specific accelerated brain aging in Parkinson's disease

    Neurobiology of aging

  2. Parkinson's disease increases brain age in Parkinson's disease patients (MAE 13.36 years (95% CI: 12.51-14.28)).

    “213 showed higher and 2 showed lower predicted brain ages than their actual ages, with a mean MAE of 13.36 years (95% confidence interval: 12.51-14.28).”

    In silicoin Parkinson's disease patientsbrainn = 215

    SAGEFusionNet: An Auxiliary Supervised Graph Neural Network for Brain Age Prediction as a Neurodegenerative Biomarker

    Brain sciences

More on Brain age

Postural control

downin humans2

2 studies
  1. Parkinson's disease is linked with worse postural control in humans during semi-tandem balance task (p = 0.016).

    “Parkinson's reported significantly poorer postural control than control, mainly for the center of pressure sway ellipse area (p = 0.016)”

    Humansduring semi-tandem balance taskn = 16

    Age- and Parkinson-related differences in trunk and lower-limb muscle activation during four balance tasks: A case-control pilot study

    Clinical biomechanics (Bristol, Avon)

  2. Parkinson's disease is linked with worse postural control in humans (compared to healthy young adults).

    “In stark contrast, older adults and individuals with Parkinson's disease exhibited control along suborthogonal directions that notably diverged from the AP and ML axes.”

    Humanscompared to healthy young adults

    Spatial variability and directional shifts in postural control in Parkinson's disease

    Clinical parkinsonism & related disorders

Motor sequence recall

downin humans1

1 study
  1. Parkinson's disease impairs motor sequence recall in humans under sequence recall conditions (Z = 2.00, p = 0.045).

    “Conversely, there was a significant group difference in the decrease of accuracy under recall conditions (Z = 2.00, p = 0.045), with the PD group showing a deviation from the distribution obtained under normal conditions (, lower panel).”

    Human trialunder sequence recall conditions36 hours

    Sleep improves accuracy, but not speed, of generalized motor learning in young and older adults and in individuals with Parkinson's disease

    Frontiers in behavioral neuroscience

  2. Parkinson's disease impairs motor sequence recall in humans (motor sequence task).

    “Participants with Parkinson's disease exhibited comparable performance to their healthy age-matched group with the exception of reduced performance in recalling motor sequences”

    Human trialmotor sequence task

    Sleep improves accuracy, but not speed, of generalized motor learning in young and older adults and in individuals with Parkinson's disease

    Frontiers in behavioral neuroscience

Glucocorticoid receptor expression

no changein mice1

1 study
  1. Parkinson's disease showed no clear effect on glucocorticoid receptor expression in mice (α-synuclein transgenic Parkinson's disease model versus age-matched controls).

    “neither differences in HPA axis-related parameters nor in splenic GC receptor expression between PD and age-matched control mice”

    Animalsα-synuclein transgenic Parkinson's disease model versus age-matched controlsspleen

    Dysregulated splenic glucocorticoid sensitivity in aging and an a-synuclein transgenic mouse model of Parkinson's disease

    Neuroimmunomodulation

More on Glucocorticoid receptor expression

Lower extremity range of motion

no changein humans1

1 study
  1. Parkinson's disease was not clearly linked with lower extremity range of motion in humans (comparison with individuals without Parkinson's disease).

    “MANOVA revealed no significant difference between lower extremity range of motion or GRF between groups”

    Humanscomparison with individuals without Parkinson's diseaselower extremity

    Rising from the Floor: A Movement Analysis of Older Adults and Individuals With Parkinson's Disease

    Perceptual and motor skills

Time to perform the Timed Supine to Stand Test

no changein humans1

1 study
  1. Parkinson's disease was not clearly linked with time to perform the Timed Supine to Stand Test in humans (comparison with individuals without Parkinson's disease, controlling for age).

    “Controlling for age via MANCOVA revealed no difference in range of motion, GRF, or time to perform the TSS.”

    Humanscomparison with individuals without Parkinson's disease, controlling for age

    Rising from the Floor: A Movement Analysis of Older Adults and Individuals With Parkinson's Disease

    Perceptual and motor skills

Timed Up and Go performance

no changein humans1

1 study
  1. Parkinson's disease showed no clear effect on timed Up and Go performance in humans (Parkinson's disease or older adults).

    “No significant differences in the effect of assistive devices were found between PwPD and older adults.”

    Human trialParkinson's disease or older adults

    Dual Task Cost with assistive device use in people with Parkinson's disease and community-dwelling older adults

    Disability and rehabilitation. Assistive technology

Blood NAD+ concentration

no changein humans1

1 study
  1. Parkinson's disease showed no clear effect on blood NAD+ concentration in humans (NAD augmentation response).

    “were not influenced by disease status or sex”

    Human trialNAD augmentation responseoral NAD precursorsblood1,200 mg/dayn = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

More on Blood NAD+ concentration

Cerebrospinal fluid inflow

downin humans1

1 study
  1. Parkinson's disease decreases cerebrospinal fluid inflow in humans.

    “Patients with PD exhibited significantly reduced CSF inflow response to ETCO2 (β values) relative to HC (p = 0.012; Fig.; Table ).”

    Human trialn = 63

    The influence of intermittent hypercapnia on cerebrospinal fluid flow and clearance in Parkinson's disease and healthy older adults

    NPJ Parkinson's disease

Alpha event-related desynchronization

downin humans1

1 study
  1. Parkinson's disease decreases alpha event-related desynchronization in response to increased visual working memory task difficulty, 500-700 ms.

    “Moreover, PD patients demonstrated significantly alpha ERD reduction at FC3, C3 and P4 in the 500-700 ms compared to the OAs.”

    Human trialin response to increased visual working memory task difficulty, 500-700 ms

    Cortical changes induced by increased cognitive task difficulty during dual task balancing correlate with postural instability in elders and patients with Parkinson's disease

    Journal of neural engineering

More on Alpha event-related desynchronization

Braking index

no changein humans1

1 study
  1. Parkinson's disease showed no clear effect on braking index in humans following first step during gait initiation.

    “Interestingly, mean BI and variability of PD patients returned to normal following this first step.”

    Human trialfollowing first step during gait initiation

    How Many Steps to Reach Steady State of Postural Stability, Progression Velocity, and Step Length during Gait Initiation? Effects of Ageing and Parkinson's Disease

    Neuro-degenerative diseases

More on Braking index

All 90

Upstream

24

SNCA

no changein mice1upin reviews1

2 studies
  1. SNCA showed no clear effect on Parkinson's disease in mice (SncaY39E or SncaS129D KI).

    “However, neurodegeneration in the substantia nigra was not observed up to 24 months of age.”

    AnimalsSncaY39E or SncaS129D KIsubstantia nigra

    Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits

    eNeuro

  2. SNCA increases Parkinson's disease.

    “This oligomeric α-syn stimulates pro-inflammatory signals, which may worsen PD symptoms and propagate chronic inflammation.”

    Review

    Alpha synuclein and inflammaging

    Heliyon

More on SNCA

Immunosenescence

upin reviews1

1 study
  1. Immunosenescence increases Parkinson's disease.

    “Immunosenescence represents a core upstream driver of Alzheimer's disease (AD) and Parkinson's disease (PD)”

    Review

    Immunosenescence as a modifiable driver of neurodegenerative diseases: Pathways and multidimensional emerging strategies for Alzheimer's and Parkinson's diseases

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Type 2 diabetes

no changein silico1OR 1.02

1 study
  1. Type 2 diabetes showed no clear effect on Parkinson's disease in silico (univariable MR) (OR 1.02, 95% CI 0.96-1.09).

    “Our MR analysis showed T2D was not associated with the risk of PD (OR: 1.02, 95% CI: 0.96-1.09, P = 0.47)”

    In silicounivariable MR

    Exploring the impacts of type 2 diabetes and metformin use on Parkinson's disease: Mendelian randomization analysis and a national cohort study

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

More on Type 2 diabetes

Peptic ulcer disease

no changein humans1HR 1.08

1 study
  1. Peptic ulcer disease was not clearly linked with Parkinson's disease in humans (HR: 1.08, 95% CI: 0.98-1.19).

    “we found no significant association in peptic ulcer (HR: 1.08, 95% CI: 0.98-1.19)”

    Humans

    Stomach infection and inflammation linked to Parkinson’s risk

    Journal of Parkinson's disease

More on Peptic ulcer disease

Atopic dermatitis

no changein humans1

1 study
  1. Atopic dermatitis was not clearly linked with Parkinson's disease in humans (atopic dermatitis).

    “allergic rhinitis (HR 1.18; 95% CI 1.14-1.22), but not atopic dermatitis.”

    Humansatopic dermatitis

    Allergic disease as a risk factor for Parkinson's disease: a possible role of eosinophil

    NPJ Parkinson's disease

More on Atopic dermatitis

Telomere length

no changein humans1

1 study
  1. Telomere length was not clearly linked with Parkinson's disease in humans (genetically predicted telomere length).

    “no causal association was found with frontotemporal dementia or Parkinson's disease”

    Humansgenetically predicted telomere length

    Association of telomere length with cognitive function and dementia: A cross-sectional NHANES analysis and 2-sample Mendelian randomization study

    Medicine

More on Telomere length

Hip osteoarthritis

no changein humans1

1 study
  1. Hip osteoarthritis was not clearly linked with Parkinson's disease in humans (Mendelian randomization using genetic variants as instrumental variables).

    “In contrast, hip OA showed no significant association with PD.”

    HumansMendelian randomization using genetic variants as instrumental variables

    Knee Osteoarthritis as a Causal Risk Factor for Parkinson's Disease: Converging Evidence From a National Survey and Genetic Analysis

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

More on Hip osteoarthritis

Systemic inflammatory response index

mediatesin humans1

1 study
  1. Systemic inflammatory response index is linked with Parkinson's disease in humans (96.42% mediated; reported 95% CI 0.93–0.98).

    “SIRI mediated 96.42% of the association (95% CI = 0.93-0.98, P < .001).”

    HumansStatistical mediation of the association between triglyceride-glucose waist-to-height ratio index and Parkinson's disease

    Association of triglyceride glucose-waist to height ratio index with Parkinson's disease and the mediating role of systemic inflammatory response index: A cross-sectional study

    Medicine

More on Systemic inflammatory response index

Usual walking pace

no changein humans1

1 study
  1. Usual walking pace was not clearly linked with Parkinson's disease in humans.

    “no such association was observed for muscle mass or walking pace genetically.”

    Humans

    Causal associations between sarcopenia and Parkinson's disease ‒ A two-sample Mendelian randomization study

    Nutricion hospitalaria

Appendicular lean mass

no changein humans1

1 study
  1. Appendicular lean mass was not clearly linked with Parkinson's disease in humans.

    “there were no significant causal associations observed for appendicular lean mass or usual walking pace with PD.”

    Humans

    Causal associations between sarcopenia and Parkinson's disease ‒ A two-sample Mendelian randomization study

    Nutricion hospitalaria

All 24

Associations

491

GLP-1 receptor agonists

downin humans13HR 0.02–0.81

13 studies
  1. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (secondary analysis vs sulfonylureas) (HR 0.56 (0.36-0.86)).

    “In the secondary analysis, GLP-1 RA use was associated with lower risks of dementia compared with sulfonylureas (0.75 (0.61-0.93)) and PD (0.56 (0.36-0.86)).”

    Humanssecondary analysis vs sulfonylureas

    GLP-1 diabetes drugs linked to lower risk of dementia

    European journal of internal medicine

  2. GLP-1 receptor agonists are associated with Parkinson's disease in humans (ranked lowest in PD risk).

    “glucagon-like peptide-1 receptor agonist (GLP-1RA) ranked lowest in patients aged <75 years.”

    Humansranked lowest in PD risk

    Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis

    Journal of global health

  3. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (patients with type 2 diabetes) (HR 0.68 (95% CI 0.54–0.85)).

    “GLP-1RA exposure was significantly associated with a reduced risk of PD in patients with T2DM (HR = 0.68, 95%CI (0.54,0.85), P = 0.001)”

    Humanspatients with type 2 diabetesn = 452,763

    Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data

    Frontiers in endocrinology

  4. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (prescribed to individuals with higher underlying risk).

    “glucagon-like peptide-1 receptor agonists were prescribed to individuals with higher underlying risk yet were associated with reduced disease incidence.”

    Humansprescribed to individuals with higher underlying risk

    Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson's disease

    Scientific reports

  5. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (compared with DPP-4i new users; iRBD and type 2 diabetes) (HR 0.02; 95% CI 0.001–0.20).

    “GLP-1RA use was associated with a lower risk of PD (HR, 0.02; 95% CI, 0.001 - 0.20)”

    Humanscompared with DPP-4i new users; iRBD and type 2 diabetesn = 148

    Association of Newer Glucose-Lowering Drugs with Incident Parkinsonian Disorders in Older Adults with REM Sleep Behavior Disorder and Type 2 Diabetes

    ADA Scientific Sessions 2026 abstract

  6. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (compared with sulfonylureas) (adjusted HR 0.81 [95% CI 0.68-0.96]).

    “use of GLP-1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease.”

    Humanscompared with sulfonylureas

    Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

    Diabetes, obesity & metabolism

  7. GLP-1 receptor agonists are associated with Parkinson's disease in humans (Patients with type 2 diabetes initiating therapy; compared with new metformin users) (aHR 0.56, 95% CI 0.34–0.93).

    “However, between years 5 and 10, GLP-1RA use was associated with a significantly lower PD risk (aHR, 0.56; 95% CI, 0.34-0.93).”

    HumansPatients with type 2 diabetes initiating therapy; compared with new metformin usersbetween years 5 and 10

    GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes

    Diabetes, obesity & metabolism

  8. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in people with type 2 diabetes (risk difference -0.002).

    “AD (RD: -0.003, p < 0.001), PD (RD: -0.002, p < 0.001), and pancreatic cancer (RD: -0.003, p < 0.001)”

    Humansin people with type 2 diabetesmore than 5-year follow-up

    Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list

    Journal of endocrinological investigation

  9. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (compared with metformin users) (HR 0.54 (95% CI 0.39–0.73)).

    “GLP-1 agonists (HR = 0.54, 95 % CI:0.39-0.73)”

    Humanscompared with metformin users

    Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

    Parkinsonism & related disorders

  10. GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (sIPTW-adjusted Cox model comparing new users with new DPP4i users) (23% lower risk; HR 0.77 (95% CI 0.63-0.95)).

    “GLP-1RA users were associated with a 23% lower risk of PD than DPP4i users (HR, 0.77; 95% CI, 0.63-0.95)”

    HumanssIPTW-adjusted Cox model comparing new users with new DPP4i usersn = 89,074

    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study

    Movement disorders : official journal of the Movement Disorder Society

All 13

More on GLP-1 receptor agonists

Smoking

downin humans11HR 0.36–0.8

11 studies
  1. Smoking is linked with a lower risk of Parkinson's disease in humans (regular smoking) (adjusted HR, 0.70; 95% CI, 0.62-0.79).

    “Regular smoking was significantly associated with elevated risks of lung cancer, ischemic heart disease, stroke, and all-cause mortality but with lower risk of PD (adjusted HR, 0.70; 95% CI, 0.62-0.79).”

    Humansregular smokingapproximately 12 yearsn = 512,701

    Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease

    JAMA neurology

  2. Smoking is linked with a lower risk of Parkinson's disease in humans (former smoking in stroke survivors) (HR = 0.80).

    “smoking (former: Hazard ratio [HR] = 0.80; current: HR = 0.66) and alcohol consumption (moderate: HR = 0.83; heavy: HR = 0.74) were associated with a lower risk of PD”

    Humansformer smoking in stroke survivors

    Vascular Risk Factors and the Risk of Incident Parkinson's Disease Among Stroke Survivors: A Nationwide Population-Based Cohort Study

    Journal of clinical medicine

  3. Smoking is linked with a lower risk of Parkinson's disease in humans (adjusted for age, race, sex, education level, APOE ε4 status, and other VRFs) (HR 0.36, 95% CI 0.21-0.61).

    “Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate”

    Humansadjusted for age, race, sex, education level, APOE ε4 status, and other VRFs

    Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study

    Neurology

  4. Smoking is associated with Parkinson's disease in humans (-8.38 per 100000 persons (95% UI: -10.72 - -6.20)).

    “the ASDR for Parkinson's disease was -8.38 per 100000 persons (95% UI: -10.72 - -6.20)”

    Humans

    Global, regional, and national burden of tobacco-related neurological disorders from 1990 to 2021: Trends and future projections

    Tobacco induced diseases

  5. Smoking is associated with Parkinson's disease in humans (history of stroke) (HR 0.80, 95% CI 0.72–0.88).

    “former smoking, hazard ratio (HR) = 0.80, 95% confidence interval (CI), 0.72–0.88”

    Humanshistory of strokeformer smoking

    Association of Vascular Risk Factors with the Risk of Parkinson’s Disease among Stroke Survivors—A Nationwide Population-Based Study

    medRxivPreprint

  6. Smoking is linked with a lower risk of Parkinson's disease in GBA1 variant carriers (OR 0.18; 95 % CI 0.05-0.62).

    “smoking was inversely associated with PD (OR 0.18; 95 % CI 0.05-0.62)”

    Humansin GBA1 variant carriers

    Exposure factors and clinical characteristics associated with Parkinson's disease in GBA1 variant carriers: A Chinese GBA1-PD intrafamilial survey

    Parkinsonism & related disorders

  7. Smoking is linked with a lower risk of Parkinson's disease in humans (1-4 years before diagnosis compared to non-smokers) (OR 2.02 [1.07-3.81] in non-smokers).

    “The odds ratio (OR [95 % CI]) associated with PD in non-smokers was 2.02 [1.07-3.81] 1-4 years before diagnosis, compared to 1.36 [1.02-1.83] at >10-year intervals (linear trend, p = 0.012).”

    Humans1-4 years before diagnosis compared to non-smokers1-4 years before diagnosisn = 502,304

    Exploring the Nicotine-Parkinson's disease link - Insights from the UK Biobank

    Parkinsonism & related disorders

  8. Smoking lowers the risk of Parkinson's disease in humans (approximately double the risk in non-smokers).

    “non-smokers have approximately double the risk of developing PD compared to smokers.”

    Review

    A paradoxical plus for Parkinson's in UK's new 'generational smoking ban'

    Journal of Parkinson's disease

  9. Smoking lowers the risk of Parkinson's disease in humans.

    “exercise and smoking are modifiable risk factors that are linked to a reduced risk of Parkinson's disease.”

    Review

    Exercise and smoking: health rivals revealing shared protective mechanisms in Parkinson's?

    NPJ Parkinson's disease

  10. Smoking lowers the risk of Parkinson's disease in humans.

    “some CVD risk factors like high LDL and smoking are associated with lower PD risk.”

    Review

    Parkinson's disease & cardiovascular disease: A narrative review

    Trends in cardiovascular medicine

All 11

More on Smoking

Alcohol

downin humans5upin humans3downin silico1HR 0.83

8 studies
  1. Alcohol is linked with a lower risk of Parkinson's disease in humans (moderate alcohol consumption in stroke survivors) (HR = 0.83).

    “alcohol consumption (moderate: HR = 0.83; heavy: HR = 0.74) were associated with a lower risk of PD”

    Humansmoderate alcohol consumption in stroke survivors

    Vascular Risk Factors and the Risk of Incident Parkinson's Disease Among Stroke Survivors: A Nationwide Population-Based Cohort Study

    Journal of clinical medicine

  2. Alcohol is linked with a higher risk of Parkinson's disease in humans (latency-adjusted semi-Markov model) (relative rate 1.61 (95% CI 1.32-1.95)).

    “latency-adjusted modeling indicated higher PD risk among drinkers (relative rate 1.61; 95% confidence interval 1.32-1.95).”

    Humanslatency-adjusted semi-Markov model

    Earlier drinking linked to higher modeled Parkinson’s risk

    Journal of Parkinson's disease

  3. Alcohol is linked with a lower risk of Parkinson's disease in humans (conventional logistic regression) (OR 0.69 (95% CI 0.53-0.91)).

    “conventional regression suggested an inverse association (odds ratio 0.69; 95% confidence interval 0.53-0.91)”

    Humansconventional logistic regression

    Earlier drinking linked to higher modeled Parkinson’s risk

    Journal of Parkinson's disease

  4. Alcohol is linked with a lower risk of Parkinson's disease in humans (OR 0.77, 95% CI 0.65-0.92).

    “Higher alcohol intake frequency was inversely associated with PD risk (OR 0.77, 95% CI 0.65-0.92)”

    Humans

    Causal associations of dietary habits and blood metabolites with Parkinson's disease risk

    Food & function

  5. Alcohol is linked with a lower risk of Parkinson's disease in humans.

    “moderate alcohol consumption may have a protective effect.”

    Humansmoderate1992 to 2021

    An epidemiological study of Parkinson's disease in Chinese older adults using the Global Burden of Disease and China Health and Retirement Longitudinal Study databases

    Neurologia i neurochirurgia polska

  6. Alcohol is associated with Parkinson's disease in humans (history of stroke) (HR 0.83, 95% CI 0.75–0.91).

    “moderate drinking, HR = 0.83, 95% CI, 0.75–0.91”

    Humanshistory of strokemoderate drinking

    Association of Vascular Risk Factors with the Risk of Parkinson’s Disease among Stroke Survivors—A Nationwide Population-Based Study

    medRxivPreprint

  7. Alcohol is associated with Parkinson's disease in humans (prediagnostic trajectory inflection point at 8.5 years) (inflection point at 8.5 years).

    “Similar patterns emerged among alcohol non-consumers, with an 8.5-year interval inflection point.”

    Humansprediagnostic trajectory inflection point at 8.5 yearsn = 502,304

    Exploring the Nicotine-Parkinson's disease link - Insights from the UK Biobank

    Parkinsonism & related disorders

  8. Alcohol lowers the risk of Parkinson's disease in silico (two-sample Mendelian randomization) (OR 0.75, 95% CI 0.60-0.93).

    “alcohol intake frequency (ORIVW=0.75, 95% CI: 0.60-0.93, P=0.010)”

    In silicotwo-sample Mendelian randomization

    Inverse Association Between Alcohol Consumption and Parkinson’s Disease Risk and Identification of RIT2 as a Linked Biomarker

    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS

  9. Alcohol raises the risk of Parkinson's disease in humans (heavy and sustained consumption).

    “heavy and sustained consumption more consistently linked to increased risk or accelerated progression of AD and PD”

    Reviewheavy and sustained consumption

    Alcohol and neurodegenerative diseases: a review of mechanistic insights and disease specific effects

    The American journal of drug and alcohol abuse

More on Alcohol

Caffeine

downin humans6mixedin humans1downin reviews1

8 studies
  1. Caffeine is linked with a lower risk of Parkinson's disease in humans (aOR 0.77, p < 0.0001).

    “Weekly caffeine consumption (adjusted odds ratio [aOR] 0.77, p < 0.0001) and tobacco use for ≥ 5 years (aOR 0.83, p = 0.0009) were inversely associated with PD”

    Humans

    Environmental determinants of Parkinson's disease and attributable burden in Latin America

    Research squarePreprint

  2. Caffeine is associated with Parkinson's disease in humans (especially in observational studies).

    “The findings indicate a consistent inverse association between caffeine consumption and the risk of developing DP, often with a dose-dependent pattern, especially in observational studies.”

    Reviewespecially in observational studies

    Evidence on the neuroprotective role of caffeine in Parkinson's disease: an integrative review

    Revista Ibero-Americana de Humanidades, Ciências e Educação

  3. Caffeine lowers the risk of Parkinson's disease in humans (relative risk ranging from 0.65 to 0.80).

    “strongly correlates with a reduced risk of PD (relative risk ranging from 0.65 to 0.80).”

    Review

    THE NEUROPROTECTIVE POTENTIAL OF COFFEE COMPOUNDS IN THE PREVENTION AND PROGRESSION OF NEURODEGENERATIVE DISORDERS: A SYSTEMATIC REVIEW FOCUSING ON ALZHEIMER’S AND PARKINSON’S DISEASES

    International Journal of Innovative Technologies in Social Science

  4. Caffeine lowers the risk of Parkinson's disease in humans.

    “Epidemiological evidence supports an inverse association between moderate caffeine intake and a reduced risk of Parkinson’s disease”

    Reviewmoderate

    Caffeine as a modulator of neurodegenerative processes: molecular targets, dose-dependent effects, and the influence of genetic polymorphism

    Russian Journal of Preventive Medicine

  5. Caffeine lowers the risk of Parkinson's disease in humans.

    “Caffeine was associated with reduced Parkinson's disease risk and slower progression.”

    Review

    The Impact of Coffee and Caffeine on Health and the possibilities of their supplementation for different populations- a narrative review

    Quality in Sport

  6. Caffeine lowers the risk of Parkinson's disease in humans.

    “higher coffee or caffeine consumption was inversely associated with PD risk.”

    Review

    Dietary Factors and Parkinson's Disease Risk: Systematic Review of Verified Observational Evidence

    Journal of Kermanshah University of Medical Sciences

  7. Caffeine lowers the risk of Parkinson's disease (Regular consumption of caffeine or caffeinated coffee).

    “regularly drinking caffeine or caffeinated coffee significantly reduces the risk of developing Alzheimer's disease, epilepsy, and Parkinson's disease.”

    ReviewRegular consumption of caffeine or caffeinated coffee

    Caffeine: A Multifunctional Efficacious Molecule with Diverse Health Implications and Emerging Delivery Systems

    International journal of molecular sciences

  8. Caffeine is associated with Parkinson's disease in humans.

    “Studies have shown an interaction between caffeine with genetic variants of MAPT, SLC2A13, LRRK2, ApoE, NOS2A, GRIN2A, CYP1A2, and ADORA2A in modulating the risk of PD.”

    Reviewin individuals with genetic variants of MAPT, SLC2A13, LRRK2, ApoE, NOS2A, GRIN2A, CYP1A2, and ADORA2An = 607,074

    Interaction between caffeine consumption & genetic susceptibility in Parkinson's disease: A systematic review

    Ageing research reviews

More on Caffeine

Nitrogen dioxide

upin humans6downin humans1OR 1.13–1.474

7 studies
  1. Nitrogen dioxide is linked with a lower risk of Parkinson's disease in humans.

    “However, NO2 showed an inverse association after full adjustment.”

    Humans

    Association Between Long-Term Exposure to Air Pollution and Parkinson's Disease: Administrative Cohort of Older Adults in South Korea

    Movement disorders : official journal of the Movement Disorder Society

  2. Nitrogen dioxide is linked with a higher risk of Parkinson's disease in humans (10 years of continuous exposure at 90th vs 0.5th percentile) (OR 1.474 (95% CI: 1.379, 1.575)).

    “for 10 years of continuous exposure to NO2 at the 90th versus the 0.5th percentile (i.e., 31.7 ppb vs. 3.7 ppb), the odds ratio for hospitalization with PD was 1.474 (95% CI: 1.379, 1.575)”

    Humans10 years of continuous exposure at 90th vs 0.5th percentile10 years

    Long-term cumulative associations of annual air pollution exposure and hospitalization with Parkinson's Disease

    Environmental epidemiology (Philadelphia, Pa.)

  3. Nitrogen dioxide is linked with a higher risk of Parkinson's disease in humans (HR 1.03, 95% CI 1.01–1.05).

    “1.03 (1.01, 1.05) for NO2”

    Humansper IQR (7.9 μg/m3)mean follow-up of 15.7 years

    Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study

    Movement disorders : official journal of the Movement Disorder Society

  4. Nitrogen dioxide is associated with Parkinson's disease in humans (Overall cohort; competing risk model) (HR 1.05, 95% CI 1.01–1.09).

    “Competing risk models confirmed elevated PD risk with NO2 (HR = 1.05; 95 % CI: 1.01-1.09) and PM10 (HR = 1.08; 95 % CI: 1.03-1.13)”

    HumansOverall cohort; competing risk modelMean follow-up 9.17 yearsn = 210,417

    Air pollution and Parkinson's disease: A prospective cohort study with sex-stratified analysis in the UK biobank

    Neurotoxicology

  5. Nitrogen dioxide is associated with Parkinson's disease in humans (Single-pollutant model) (HR 1.74 (95% CI 1.68–1.80)).

    “These associations remained robust in the multipollutant model.”

    HumansSingle-pollutant model11.2±2.4 years47.3% mensn = 5,113,322

    Long-term exposure to multiple air pollutants and risk of Parkinson's disease: a population-based multipollutant model study

    Journal of neurology, neurosurgery, and psychiatry

  6. Nitrogen dioxide is linked with a higher risk of Parkinson's disease in humans (first hospitalization with a PD-related diagnosis) (IRR 1.07 (95% CI: 1.05, 1.08)).

    “1.07 (95% CI: 1.05, 1.08), and 1.03 (95% CI: 1.02, 1.05) for an interquartile range increase in PM2.5 (3.72 μg/m3), NO2 (13.84 ppb)”

    Humansfirst hospitalization with a PD-related diagnosis13.84 ppb IQR increaseannual

    The effect of air pollution on hospitalizations with Parkinson's disease among medicare beneficiaries nationwide

    NPJ Parkinson's disease

  7. Nitrogen dioxide is associated with Parkinson's disease in humans (OR 1.13, 95% CI 1.07-1.19).

    “Greater NO2 exposure was also associated with increased PD risk when comparing the top quintile with the bottom quintile”

    HumansTop versus bottom quintile2000 to 2014

    Air Pollution and Parkinson Disease in a Population-Based Study

    JAMA network open

More on Nitrogen dioxide

Fine particulate matter

upin humans7HR 1.018–2.65

7 studies
  1. Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (per interquartile range (4.3 μg/m3) increase) (HR 1.018, 95% CI 1.008-1.028).

    “each IQR increase in PM2.5 (4.3 μg/m3) and O3 (7.3 ppb) was associated with a modestly increased PD incidence (PM2.5: HR = 1.018, 95% CI: 1.008-1.028”

    Humansper interquartile range (4.3 μg/m3) increase

    Association Between Long-Term Exposure to Air Pollution and Parkinson's Disease: Administrative Cohort of Older Adults in South Korea

    Movement disorders : official journal of the Movement Disorder Society

  2. Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (10 years of continuous exposure at 90th vs 0.5th percentile) (OR 1.634 (95% CI: 1.489, 1.792)).

    “the odds ratio for hospitalization with PD was 1.634 (95% CI: 1.489, 1.792)”

    Humans10 years of continuous exposure at 90th vs 0.5th percentile10 years

    Long-term cumulative associations of annual air pollution exposure and hospitalization with Parkinson's Disease

    Environmental epidemiology (Philadelphia, Pa.)

  3. Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (HR 1.05, 95% CI 1.03–1.07).

    “Hazard ratios (95% confidence intervals) for associations between air pollutants (per IQR) and PD incidence were: 1.05 (1.03, 1.07) for PM2.5”

    Humansper IQR (2.0 μg/m3)mean follow-up of 15.7 years

    Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study

    Movement disorders : official journal of the Movement Disorder Society

  4. Fine particulate matter is associated with Parkinson's disease in humans (Single-pollutant model) (HR 2.65 (95% CI 2.59–2.72)).

    “exposure to PM2.5 (HR 2.65 (95% CI 2.59 to 2.72)), PM10 (HR 3.13 (3.04 to 3.22)), NO2 (HR 1.74 (1.68 to 1.80)) and SO2 (HR 1.68 (1.65 to 1.71)) was associated with an increased risk of PD.”

    HumansSingle-pollutant model11.2±2.4 years47.3% mensn = 5,113,322

    Long-term exposure to multiple air pollutants and risk of Parkinson's disease: a population-based multipollutant model study

    Journal of neurology, neurosurgery, and psychiatry

  5. Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (first hospitalization with a PD-related diagnosis) (IRR 1.08 (95% CI: 1.07, 1.10)).

    “incidence rate ratios of 1.08 (95% CI: 1.07, 1.10), 1.07 (95% CI: 1.05, 1.08), and 1.03 (95% CI: 1.02, 1.05) for an interquartile range increase in PM2.5”

    Humansfirst hospitalization with a PD-related diagnosis3.72 μg/m3 IQR increaseannual

    The effect of air pollution on hospitalizations with Parkinson's disease among medicare beneficiaries nationwide

    NPJ Parkinson's disease

  6. Fine particulate matter is associated with Parkinson's disease in humans (Populations within metropolitan cores) (OR 1.23, 95% CI 1.11-1.35).

    “Greater PM2.5 exposure was associated with increased PD risk, and this risk was greatest after restricting to populations within metropolitan cores”

    HumansPopulations within metropolitan coresTop versus bottom quintile1998 to 2015

    Air Pollution and Parkinson Disease in a Population-Based Study

    JAMA network open

  7. Fine particulate matter raises the risk of Parkinson's disease in humans (10% (1.10; 1.03-1.19)).

    “For every 5 μg/m3 and 15 μg/m3 increase of Particulate Matter 2.5 (PM2.5) and PM10 concentration, estimated (95% Confidence Interval) PD risk was 10% (1.10; 1.03-1.19)”

    Review5 μg/m3 increase

    Association of long-term outdoor air pollution exposure with incidence of Parkinson's disease, multiple sclerosis and motor neuron diseases: a systematic review and meta-analysis

    Environment international

More on Fine particulate matter

Diabetes mellitus

upin humans7HR 1.38

7 studies
  1. Diabetes mellitus is linked with a higher risk of Parkinson's disease in humans (duration ≥ 5 years in stroke survivors) (HR = 1.38).

    “diabetes mellitus, especially with a duration ≥ 5 years, was associated with increased PD risk (HR = 1.38)”

    Humansduration ≥ 5 years in stroke survivors≥ 5 years

    Vascular Risk Factors and the Risk of Incident Parkinson's Disease Among Stroke Survivors: A Nationwide Population-Based Cohort Study

    Journal of clinical medicine

  2. Diabetes mellitus is linked with a higher risk of Parkinson's disease in humans.

    “Analysis of the CHARLS data showed that aging, urban residence, and metabolic diseases such as diabetes, hypertension, and dyslipidemia were significantly associated with the risk of PD”

    Humans1992 to 2021

    An epidemiological study of Parkinson's disease in Chinese older adults using the Global Burden of Disease and China Health and Retirement Longitudinal Study databases

    Neurologia i neurochirurgia polska

  3. Diabetes mellitus is associated with Parkinson's disease in humans (Univariate and multivariate analyses).

    “Age, male sex, and diabetes mellitus demonstrated a significant positive association with PD development in a univariate and multivariate analyses.”

    HumansUnivariate and multivariate analyses

    Parkinson's disease incidence in glaucoma patients from israel: insights from a 20-year follow-up sample

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

  4. Diabetes mellitus is associated with Parkinson's disease in humans (history of stroke) (HR 1.38, 95% CI 1.25–1.52 for diabetes duration ≥5 years; P for trend <.001).

    “particularly in those with a duration of diabetes mellitus of ≥5 years (HR = 1.38, 95% CI, 1.25–1.52).”

    Humanshistory of strokediabetes mellitus for ≥5 years

    Association of Vascular Risk Factors with the Risk of Parkinson’s Disease among Stroke Survivors—A Nationwide Population-Based Study

    medRxivPreprint

  5. Diabetes mellitus is linked with a higher risk of Parkinson's disease in humans (prior to diagnosis).

    “Our findings show that certain disorders elevate AD and PD risk before AD and PD diagnosis including: insulin and non-insulin dependent diabetes mellitus, noninfective gastro-enteritis and colitis, functional intestinal disorders, and bacterial intestinal infections”

    Humansprior to diagnosis

    Gut-Brain Nexus: Mapping Multi-Modal Links to Neurodegeneration at Biobank Scale

    medRxiv : the preprint server for health sciencesPreprint

  6. Diabetes mellitus raises the risk of Parkinson's disease in humans.

    “diabetes mellitus—and even its precursor stages—increase the risk of developing Parkinson's disease over the course of one's life.”

    Review

    Effects of diet in focus - Diabetes increases the risk of Parkinson's disease

    Diabetes aktuell

  7. Diabetes mellitus raises the risk of Parkinson's disease in individuals with diabetes mellitus.

    “Chronic hyperglycemia and insulin resistance, which characterize diabetes mellitus (DM), have been reported to alter dopaminergic activity, increase the risk of PD”

    Reviewin individuals with diabetes mellitus

    Frailty and Parkinson's disease: the role of diabetes mellitus

    Frontiers in medicine

More on Diabetes mellitus

Mortality

upin humans7OR 1.277

7 studies
  1. Parkinson's disease is linked with a higher risk of mortality in humans (4-fold).

    “Self-reported PD incidence was 0.13% over a median of 4.8 years follow-up, but cases had a 4-fold higher mortality”

    Humansmedian of 4.8 years

    A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort

    NPJ Parkinson's disease

  2. Parkinson's disease is associated with mortality in humans (Hospitalized COVID-19 patients in Brazil; multivariable analysis) (Adjusted OR 1.277, 95% CI 1.198–1.360).

    “Multivariable analysis confirmed Parkinson's disease as an independent mortality risk factor (OR = 1.277; 95% CI = 1.198-1.360).”

    HumansHospitalized COVID-19 patients in Brazil; multivariable analysisMarch 2020 to March 2024n = 1,725,690

    Characterization of the Epidemiological Profile of Patients With Parkinson's Disease Who Were Hospitalized due to SARS-CoV-2 Infection: A Portrait of 4 Years of the Pandemic in Brazil

    Journal of medical virology

  3. Parkinson's disease is associated with mortality in humans (Patients with cancer; adjusted for potential confounders) (Adjusted HR 1.37, 95% CI 1.25–1.51).

    “Comorbid Parkinson's disease was independently associated with 5-year mortality”

    HumansPatients with cancer; adjusted for potential confounders5 yearsn = 118,999

    Effects of Parkinson's disease on survival in cancer survivors: a retrospective, multicentre cohort study in Japan

    Brain communications

  4. Parkinson's disease is linked with a higher risk of mortality in humans (adjusted HR = 1.62; 95% confidence interval [CI] = 1.31-2.01).

    “PD was associated with a significantly increased mortality risk (adjusted HR = 1.62; 95% confidence interval [CI] = 1.31-2.01).”

    Humans23 years

    Twenty-Three-Year Mortality in Parkinson's Disease: A Population-Based Prospective Study (NEDICES)

    Journal of clinical medicine

  5. Parkinson's disease is associated with mortality in humans (adjusted HR = 2.24 with AAs; 2.44 without AAs).

    “Both groups were associated with increased mortality compared to non-PD (adjusted HR = 2.24 with AAs; 2.44 without AAs).”

    Humans

    Anticholinergic use is associated with lower mortality but not increased hip fracture risk in Parkinson's disease patients: a retrospective cohort study

    BMC geriatrics

  6. Parkinson's disease is linked with a higher risk of mortality in humans.

    “Individuals with PD have a significantly higher risk of all-cause mortality compared to those without PD (HR = 1.747 [1.363-2.238], P < 0.001) among adults.”

    Humans

    Association of inflammation/nutrition-based indicators with Parkinson's disease and mortality

    Frontiers in nutrition

  7. Parkinson's disease is associated with mortality in humans.

    “Parkinson's disease (PD) is associated with an increased rate of mortality.”

    Review

    Other conditions do not fully explain Parkinson’s higher death rate

    European journal of neurology

Frailty

upin humans6+42%OR 1.7–3.92

6 studies
  1. Parkinson's disease is associated with frailty in humans (Parkinson's disease) (41.9%).

    “frailty was detected in 26 (41.9%)”

    HumansParkinson's diseasen = 62

    Sarcopenia and frailty in Parkinson's disease: A cross-sectional analytical study

    Pakistan journal of medical sciences

  2. Frailty is associated with Parkinson's disease in humans (five years prior to PD diagnosis) (OR = 1.70, 95% CI 1.62-1.78).

    “Mildly frail (OR = 1.70, 95 % CI 1.62-1.78) and moderately-to-severely frail (OR = 1.29, 95 % CI 1.16-1.43) were associated with PD five years prior to diagnosis.”

    Humansfive years prior to PD diagnosis12 months

    Frailty in prodromal Parkinson's disease in Medicare beneficiaries

    Parkinsonism & related disorders

  3. Parkinson's disease predicts frailty in humans (cause-specific HR 1.66 (95% CI 1.07-2.56)).

    “cause-specific hazard ratios were 1.66 (95% CIs 1.07-2.56), 1.78 (95% CIs 1.05-3.03), and 1.58 (95% CIs 0.91-2.74). Similar results were found for parkinsonism.”

    Humans4 yearsn = 12,865

    Cross-Sectional and Prospective Associations between Parkinsonism and Parkinson's Disease with Frailty in Latin America

    Movement disorders clinical practice

  4. Parkinson's disease is associated with frailty in humans (OR 2.49 (95% CI 1.87-3.31)).

    “PD was associated with baseline and incident frailty after accounting for age, sex, and education: odds ratios and 95% confidence intervals (95% CI) for frailty were 2.49 (95% CIs 1.87-3.31)”

    Humans4 yearsn = 12,865

    Cross-Sectional and Prospective Associations between Parkinsonism and Parkinson's Disease with Frailty in Latin America

    Movement disorders clinical practice

  5. Parkinson's disease is associated with frailty in humans (OR 3.920, 95% CI 1.005-15.295).

    “Parkinson's disease (P = 0.049, OR = 3.920, 95% CI 1.005-15.295)”

    Humansn = 457

    Association Between Chronic Diseases and Frailty in a Sample of Older Greek Inpatients

    Cureus

  6. Frailty is associated with Parkinson's disease in humans (prefrail/frail populations).

    “Large cohorts suggest prefrailty/frailty is associated with incident PD risk”

    Reviewprefrail/frail populations

    Parkinson's Disease and Frailty: A Two-Way Link Across Aging

    Journal of clinical medicine

  7. Parkinson's disease is associated with frailty in people with Parkinson's disease.

    “Frailty worsened as Parkinson symptoms became more severe”

    Reviewin people with Parkinson's disease

    Frailty in Patients With Parkinson's Disease in Community and Clinical Settings: A Scoping Review

    Western journal of nursing research

SGLT2 inhibitors

downin humans6HR 0.03–0.7

6 studies
  1. SGLT2 inhibitors are associated with Parkinson's disease in humans (ranked lowest in PD risk among older adults).

    “Rank probability analyses suggested that sodium-glucose co-transporter-2 inhibitors (SGLT2i) tended to rank lowest in PD risk among older adults (≥75 years)”

    Humansranked lowest in PD risk among older adults

    Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis

    Journal of global health

  2. SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with DPP-4i new users; iRBD and type 2 diabetes) (HR 0.03; 95% CI 0.001–0.97).

    “SGLT-2i use was associated with a lower risk of PD (HR, 0.03; 95% CI, 0.001 - 0.97), parkinsonism (HR, 0.02; 95% CI, 0.001 - 0.87)”

    Humanscompared with DPP-4i new users; iRBD and type 2 diabetesn = 138

    Association of Newer Glucose-Lowering Drugs with Incident Parkinsonian Disorders in Older Adults with REM Sleep Behavior Disorder and Type 2 Diabetes

    ADA Scientific Sessions 2026 abstract

  3. SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with metformin users in T2DM patients) (28% lower; aHR 0.72 (95% CI 0.62-0.84)).

    “SGLT2i users had a 28% lower adjusted hazard ratio (aHR) for PD (0.72; 95% CI, 0.62-0.84)”

    Humanscompared with metformin users in T2DM patientsn = 913,428

    SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes

    Journal of Parkinson's disease

  4. SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with other oral antidiabetic drugs; 6-month drug use lag period) (aHR 0.80 (95% CI 0.69-0.91)).

    “and PD (aHR 0.80, 95% CI 0.69-0.91)”

    Humanscompared with other oral antidiabetic drugs; 6-month drug use lag periodn = 358,862

    SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes

    Neurology

  5. SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with DPP4 inhibitors, after 1:1 propensity score matching) (HR 0.70 [95% CI 0.55-0.89]; 2.5 vs 3.5 events per 1000 person-years).

    “The SGLT2 inhibitor group was associated with a significantly lower risk of incident PD than the DPP4 inhibitor group”

    Humanscompared with DPP4 inhibitors, after 1:1 propensity score matching

    Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes

    Diabetes, obesity & metabolism

  6. SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with metformin users) (HR 0.15 (95% CI 0.10–0.21)).

    “SGLT2 inhibitors (HR = 0.15, 95 % CI:0.10-0.21)”

    Humanscompared with metformin users

    Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

    Parkinsonism & related disorders

More on SGLT2 inhibitors

DPP-4 inhibitors

downin humans3OR 0.54–1.78

3 studies
  1. DPP-4 inhibitors lower the risk of Parkinson's disease in humans (OR 0.54 (95% CI 0.32–0.92)).

    “DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92])”

    Human trial

    Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials

    Diabetes, obesity & metabolism

  2. DPP-4 inhibitors are associated with Parkinson's disease in humans (Reported OR 1.78 (95% CI 1.21-2.61) for IVeQTL; 1.21 (1.02-1.45) for IVpQTL).

    “Genetically proxied DPP-4 inhibition was associated with reduced PD risk”

    HumansGenetically proxied inhibition; direction follows the abstract's interpretation, although reported odds ratios exceed 1

    Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  3. DPP-4 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with metformin users) (HR 0.60 (95% CI 0.53–0.67)).

    “DPP4 inhibitors (HR = 0.60, 95 % CI:0.53-0.67)”

    Humanscompared with metformin users

    Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

    Parkinsonism & related disorders

More on DPP-4 inhibitors

Retinal vessel density

downin humans1

1 study
  1. Retinal vessel density is associated with Parkinson's disease in humans (disease duration in patients with Parkinson's disease undergoing yoga) (r = -0.67).

    “Changes in RVD were significantly correlated with disease duration (r = -0.67; P = 0.007)”

    Human trialdisease duration in patients with Parkinson's disease undergoing yogaretina24 weeksn = 17

    Retinal neurovascular signatures in response to 6-month yoga exercise in patients with Parkinson's Disease

    Parkinsonism & related disorders

More on Retinal vessel density

Cognitive resource demand during walking

upin humans1

1 study
  1. Parkinson's disease is associated with cognitive resource demand during walking in humans during walking.

    “during walking, the need for cognitive resources increases with age and with Parkinson's disease.”

    Human trialduring walking

    Normal aging and Parkinson's disease: deciphering the neurophysiological changes affecting gait

    Soins. Gerontologie

Margin of stability

mixedin humans1

1 study
  1. Parkinson's disease is associated with margin of stability in humans during gait initiation.

    “Descriptive statistics revealed a significant effect of the group (YH vs. EH vs. PD) and velocity condition (SVC vs. MVC) on the MoS”

    Human trialduring gait initiation

    Evaluation of the Margin of Stability during Gait Initiation in Young Healthy Adults, Elderly Healthy Adults and Patients with Parkinson's Disease: A Comparison of Force Plate and Markerless Motion Capture Systems

    Sensors (Basel, Switzerland)

More on Margin of stability

All 491

Trial sponsors

  • Bial - Portela C

    Company37 trialsPhase 42,588 people

  • UCB

    Company12 trialsPhase 41,654 people

  • Teva

    Company11 trialsPhase 43,681 people

  • GSK

    Company10 trialsPhase 42,110 people

  • Otsuka

    Company5 trialsPhase 4998 people

  • Novartis

    Company5 trialsPhase 4809 people

  • Sandoz

    Company2 trialsPhase 4152 people

  • MDD US Operations

    Company2 trialsPhase 4140 people

Funding

161 grants since 2016

National Institute of Neurological Disorders and Stroke$77.7MUS Department of Veterans AffairsNational Institute on Aging$12.2M

Latest

JAMA Neurology

Agent Orange exposure linked to Parkinson disease in US veterans

Compared with unexposed veterans, those reporting exposure had a higher relative risk of Parkinson disease diagnosis, with a hazard ratio of 1.44.Compared with unexposed veterans, those reporting exposure had a higher relative risk of Parkinson disease diagnosis, with a hazard ratio of 1.44.

Cohort · 4,468,509 peopleParkinson's disease
medRxiv

Wrist tracking model detected Parkinson’s in people

The model scored 0.93 on a measure of how well it distinguished 133 people with Parkinson’s from 26 healthy controls.The model scored 0.93 on a measure of how well it distinguished 133 people with Parkinson’s from 26 healthy controls.

Preprint: case-control studyParkinson's disease

See all 6,117 papers on Parkinson's disease